

HCL Technologies

Improving durability

Maintain BUY on HCL Tech (HCLT) based on relative outperformance, in-line 4Q rev, operational improvement and business durability (large deals, infra services, software business). HCLT's software portfolio and strong presence in infra services (cloud migration, virtual workplace, endpoint management) will mitigate the near-term headwinds of volume/price compression & deferrals. Our TP of Rs 565, values HCLT at a modest 12x FY22E EPS (3-6% EPS increase).

- Highest growth within peers. HCLT's revenue stood at USD 2,543mn, +0.8/13.5% QoQ/YoY cc including organic +6% YoY. FY20 growth at 16.7% cc included 10.7% organic growth (highest within peers). Early response towards BCP translated into negligible COVID-19 impact on 4Q performance. Short-term impact of (1) Volume-based billing, (2) Pricing discounts (temporary), (3) EN deals slowdown & deferral/pause in discretionary, and (4) Payment extension expected to be higher in Manufacturing vertical (Auto, Aero sub-vertical).
- Large deal ramp to support recovery from 2Q. Despite the headwinds in Mar-20, HCLT signed 14 transformational deals with record bookings in 4Q. 2QFY21 trajectory is expected to improve supported by ramp-up of large deals such as Stanley, Black & Decker. Mgmt stated that renewals are tracking well and no long-term impact is seen on longer duration deals due to COVID-19 situation. Growth recovery is predicated on (1) 53 transformational signings in FY20 (5 clients added to >USD 100mn bucket), (2) Cross-sell opportunities in infra services, and (2) 11% growth in RPO for next year.
- P&P provides rev/margin stability. HCLT expanded its partnerships across MS Azure, AWS, GCP, IBM and Cisco and also launched new releases across its products-AppScan, BigFix, Unica and DRYiCE. Strong velocity in products is supported by geo diversification, business criticality, sustainable operating profile (>30% EBIT) and provide stability/resilience to HCLT.
- Operational outperformance. EBIT margin was higher at 20.9%, +64bps QoQ supported by increase in IT & Business services margin (led by Mode-2 growth/margin). Margin improvement supported by INR deprecation (+53bps QoQ) and operational efficiencies, offsetting higher amortisation. Cash conversion improved in FY20 with OCF/EBITDA at 81% as compared to 64% in FY19.
- Valuation and view. We've factored flat revenue in FY21 (~1.5% organic decline) and EBIT% decline of 100bps, reverting in FY22 (at FY20 level) with 8% rev growth in FY22E. Factored 1% decline in IT & BS, 6% decline in ER&D and 14% growth in P&P (1% organic) for FY21E. Valuation discount to peers on lower RoIC/FCF due to capex/acquisition intensity, despite the growth outperformance; currently at 10.9x FY22E (5/10-yr avg. at 14x).

Financial Summary

Filialiciai Suli	iiiiai y									
YE Mar (Rs bn)	4Q FY20	4Q FY19	YoY (%)	3Q FY20	QoQ (%)	FY18	FY19	FY20	FY21E	FY22E
Net Revenues	185.90	159.90	16.3	181.35	2.5	505.69	604.27	706.78	724.08	794.85
EBIT	38.81	30.39	27.7	36.70	5.7	99.87	118.21	140.30	136.44	158.95
APAT	31.54	25.68	22.8	30.37	3.9	87.80	101.23	110.62	105.12	127.20
Diluted EPS (Rs)	11.6	9.5	22.8	11.2	3.9	32.4	37.3	40.8	38.8	46.9
P/E (x)						15.8	13.7	12.5	13.2	10.9
EV / EBITDA (x)						11.6	9.5	7.9	7.8	6.3
RoE (%)						25.3	26.0	23.8	19.0	19.9

Source: Company, HSIE Research

BUY

CMP (as on 07 l	Rs 511	
Target Price	Rs 565	
NIFTY	9,199	
KEY CHANGES	OLD	NEW
Rating	Buy	Buy
Price Target	Rs 525	Rs 565
EDC 0/	FY21E	FY22E
EPS %	3.2%	6.8%

KEY STOCK DATA

Bloomberg code	HCLT IN
No. of Shares (mn)	2,714
MCap (Rs bn) / (\$ mn)	1,389/18,318
6m avg traded value (Rs n	nn) 2,388
52 Week high / low	Rs 624/375

STOCK PERFORMANCE (%)

	3M	6 M	12M
Absolute (%)	(15.8)	(10.9)	(9.6)
Relative (%)	7.8	11.8	8.3

SHAREHOLDING PATTERN (%)

	Dec-19	Mar-20
Promoters	59.88	60.33
FIs & Local MFs	8.38	9.07
FPIs	27.66	26.42
Public & Others	4.08	4.18
Pledged Shares	0.00	0.00
Source : BSE		

Apurva Prasad

apurva.prasad@hdfcsec.com +91-22-6171-7327

Amit Chandra

amit.chandra@hdfcsec.com +91-22-6171-7345

Vinesh Vala

vinesh.vala@hdfcsec.com +91-22-6171-7332



Revenue at USD 2,543mn, +0.8/13.5% QoQ/YoY CC (6% YoY CC organic growth), led by IT & Business services

EBIT% expanded by 64bps QoQ aided by currency tailwind (+53bps) and productivity in IT business services (+22bps), partially offset by increase in amortisation cost (-11bps)

APAT at Rs 31.54bn was supported by healthy margins (Mode-2 margin expansion)

Quarterly consolidated Financial Snapshot

Particulars (Rs bn)	4QFY20	4QFY19	YoY (%)	3QFY20	QoQ (%)
Net Revenues (USD mn)	2,543	2,278	11.7	2,543	0.0
Net Revenues	185.90	159.90	16.3	181.35	2.5
Direct Costs	114.79	104.21	10.2	115.10	-0.3
Gross Profit	71.11	55.69	27.7	66.25	7.3
SG&A Expenses	23.91	19.72	21.2	21.55	11.0
EBITDA	47.20	35.97	31.2	44.70	5.6
Depreciation	8.39	5.58	50.4	8.00	4.9
EBIT	38.81	30.39	27.7	36.70	5.7
Other Income	-0.13	1.52	NA	0.67	NA
PBT	38.68	31.91	21.2	37.37	3.5
Tax	7.06	6.15	14.8	6.92	2.0
APAT	31.54	25.68	22.8	30.37	3.9
E/o (adj for tax)	-	-		-	
RPAT	31.54	25.68	22.8	30.37	3.9


Source: Company, HSIE Research

Margin Analysis

Particulars (% of Revenue)	4QFY20	4QFY19	YoY (bps)	3QFY20	QoQ (bps)
Direct Costs	61.7	65.2	-342	63.5	-172
Gross Profit Margin (%)	38.3	34.8	342	36.5	172
SG&A Expenses	12.9	12.3	53	11.9	98
EBITDA Margin (%)	25.4	22.5	289	24.6	74
EBIT Margin (%)	20.9	19.0	187	20.2	64
Tax Rate (%)	18.3	19.3	-102	18.5	-27
APAT Margin (%)	17.0	16.1	91	16.7	22


Source: Company, HSIE Research

Revenue Growth Trajectory (% QoQ)




Source: Company, HSIE Research

Revenue Growth Trajectory (% YoY)




HDFC securities

EBIT Margin Trajectory (%)




Source: Company, HSIE Research

Revenue Mix By Vertical (%)




Source: Company, HSIE Research; 4QFY20

Revenue Mix by Segment (%)




Source: Company, HSIE Research; 4QFY20

HCLT's Transformational Deal Trend




Source: Company, HSIE Research

Revenue Mix By Geography (%)



Source: Company, HSIE Research; 4QFY20

Revenue Growth by Segment (% YoY CC)





HCLT leads among tier-1 IT peers with revenue growth of 13.5% YoY CC (organic growth 6%) in 4QFY20


EBIT margin gap narrows between INFY (21.2%) and HCLT (20.9%) in 4O

Industry-leading organic growth of 10.7% among Tier- 1 IT companies in FY20, outperformance to continue based on infra services cross-sell, velocity in P&P portfolio and ramp-up of large deals from 2Q

HCLT reported marginal expansion in its EBIT% supported by P&P business, as compared to decline by all Tier 1-IT peers in FY20


Multiple cost levers such as variable pay, sub-contracting, granular utilisation management, travel cost & discretionary spend

Growth leadership: Revenue Growth Trend (% YoY CC) vs. peers




Source: Company, HSIE Research, * HCLT organic growth of 6%

Relative outperformance in margins: EBIT Margin Trend (%) vs. peers




Source: Company, HSIE Researh

Growth leadership (including organic): FY20 Revenue Growth (% YoY CC)



Source: Company, HSIE Research, * HCLT organic growth of 10.7%

Higher durability in operations supported by P&P: FY20 EBIT% change (YoY bps)



INSTITUTIONAL RESEARCH

Segment-wise, IT BS grew 1.6% QoQ supported by Infra services, while ER&D declined 1.8% QoQ due to COVID 19 impact

Mfg (Auto/Aerospace) to be biggest impacted due to COVID-19 situation

Financial services expected to have only modest impact supported by spend on digital channels, vendor/captive consolidation opportunities

Despite relative strength in Telecom vertical, client-specific issue to impact its near-term performance

Multiple RTB consolidation opportunities in E&U despite muted industry outlook

IBM product acquisition payment tranche of USD 812mn in 1QFY21 (USD 812mn paid till Jun-19)

Vertical-wise Revenue Growth

(YoY, % CC)	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20
Manufacturing	-3.9	-3.9	1.5	6.7	28.3	26.0	27.0	26.7
Technology & Services	39.5	36.3	24.4	25.9	20.0	41.5	43.0	38.7
Financial Services	2.9	2.3	0.1	-1.4	0.9	8.5	4.3	1.5
Life Sciences and Healthcare	18.1	19.8	23.4	28.2	16.0	16.3	5.4	3.4
Public Services	3.4	13.3	8.1	21.8	18.0	7.1	7.8	-1.3
Telecom, Media, Publishing & Entertainment	-0.1	-0.8	40.3	33.4	28.2	34.3	8.2	6.0
Retail & CPG	5.3	19.2	21.5	20.9	22.1	9.9	4.2	4.1
Total	8.5	10.5	13.0	15.3	17.0	20.5	16.4	13.5

Source: Company, HSIE Research, Reclassified from 1QFY19, Prior acquisition methodology

Geographic Revenue Growth

(YoY, % CC)	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20
Americas	11.9	15.1	12.9	15.1	21.3	22.6	21.2	20.4
Europe	9.3	3.5	14.5	18.7	11.3	19.9	9.5	2.4
Rest of the World	-15.5	0.7	8.4	4.7	1.6	4.4	0.8	-1.3
Total	8.5	10.5	13.0	15.3	17.0	20.5	16.4	13.5

Source: Company, HSIE Research, Prior acquisition methodology

Headcount, Attrition and Utilisation Data

(Nos.)	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20
Total headcount	124,121	127,875	132,328	137,965	143,900	147,123	149,173	150,423
Technical	113,404	116,910	121,273	126,717	132,384	135,957	137,725	139,302
Support	10,717	10,965	11,055	11,248	11,516	11,166	11,448	11,121
Gross additions	12,558	11,683	11,055	11,248	16,332	13,430	11,502	10,278
Net additions	4,040	3,754	4,453	5,637	5,935	3,223	2,050	1,250
Voluntary LTM attrition (%)	16.3	17.1	17.8	17.7	17.3	16.9	16.8	16.3

Source: Company, HSIE Research

Business Segment Contribution

(% of rev)	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20
Mode 1	73.4	72.0	71.0	70.5	70.3	67.0	66.0	65.1
Mode 2	15.7	16.0	17.2	18.9	18.8	18.3	18.2	19.2
Mode 3	11.0	12.0	11.9	10.6	10.9	14.7	15.8	15.7
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Source: Company, HSIE Research

Business Segment Revenue growth

(QoQ, %)	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20
Mode 1	NA	0.3	3.2	2.9	3.5	0.2	0.8	-1.4
Mode 2	NA	4.5	12.2	14.1	3.3	2.5	1.5	5.6
Mode 3	NA	11.1	4.8	-8.0	6.6	41.5	10.1	-0.5
Total	0.8	2.1	4.9	3.5	3.8	5.2	2.3	0.0



Key Assumptions

Particulars	FY20	FY21E	FY22E
IT and Business Services	10.7	-1.0	8.5
Engineering & R&D services	12.4	-6.2	7.3
Products & Platform	60.3	14.0	8.3
Total USD revenue growth (%)	15.1	-0.2	8.3
USD/INR rate	71.1	73.0	74.0
EBIT margin (%)	19.9	18.8	20.0

Source: HSIE Research

Change in Estimates

	FY21E			FY22E				
(Rs bn)	Earlier	New	% Change	Earlier	New	% Change		
Revenue (USD Mn)	10,061	9,919	-1.4	10,841	10,741	-0.9		
Revenue	734.44	724.08	-1.4	802.21	794.85	-0.9		
EBIT	134.32	136.44	1.6	151.20	158.95	5.1		
EBIT Margin (%)	18.3	18.8	55bps	18.8	20.0	115bps		
EPS (Rs)	37.5	38.8	3.2	43.9	46.9	6.8		

Source: HSIE Research



Peer Set Comparison

MCap		CMP	TP	RECO	EPS (Rs)			P/E (x)			RoE (%)					
Company	(Rs bn)	(Rs)	(Rs)	RECO	FY19	FY20	FY21E	FY22E	FY19	FY20	FY21E	FY22E	FY19	FY20	FY21E	FY22E
TCS*	7,115	1,896	1,680	REDUCE	83.9	86.2	78.9	88.3	22.6	22.0	24.0	21.5	36.1	37.3	35.1	38.9
Infosys*	2,831	667	680	BUY	37.1	38.6	36.7	42.4	17.9	17.3	18.2	15.7	24.3	25.2	23.2	25.3
HCL Tech*	1,385	511	565	BUY	37.3	40.8	38.8	46.9	13.7	12.5	13.2	10.9	26.0	23.8	19.0	19.9
Wipro*	1,051	184	185	REDUCE	15.8	17.0	15.6	17.0	11.7	10.8	11.8	10.9	17.3	17.3	14.9	14.2
TechM*	499	517	625	BUY	48.9	48.3	42.4	48.0	10.6	10.7	12.2	10.8	22.0	20.2	16.5	17.4
Tier-1 IT Median									13.7	12.5	13.2	10.9	24.3	23.8	19.0	19.9
LTI	277	1,593	1,650	ADD	87.1	86.2	93.1	109.9	18.3	18.5	17.1	14.5	34.6	28.2	26.3	27.0
Mphasis	141	756	800	ADD	57.6	60.4	59.6	66.9	13.1	12.5	12.7	11.3	20.0	20.5	18.6	19.3
L&T Tech	124	1,185	1,215	ADD	67.8	77.2	72.9	86.7	17.5	15.4	16.3	13.7	32.0	29.8	24.4	25.2
Mindtree*	145	883	830	ADD	44.1	40.5	43.7	55.1	20.0	21.8	20.2	16.0	24.9	19.5	21.6	24.0
Hexaware*#	73	245	300	ADD	19.6	21.5	19.8	22.9	12.5	11.4	12.4	10.7	26.5	24.9	20.2	20.9
Persistent*	41	532	525	REDUCE	47.8	47.0	37.1	43.9	11.1	11.3	14.3	12.1	15.7	14.4	11.5	12.6
Cyient*	26	233	240	REDUCE	44.4	33.8	23.2	26.7	5.2	6.9	10.1	8.7	19.5	13.4	9.8	10.8
Zensar	19	83	95	ADD	14.2	10.3	9.2	11.8	5.8	8.0	9.1	7.0	17.6	11.5	9.4	11.2
Sonata	22	217	250	BUY	23.7	27.3	22.4	27.5	9.1	7.9	9.7	7.9	35.1	34.6	25.6	28.6
Majesco	8	285	360	BUY	18.3	18.0	20.5	24.8	15.5	15.8	13.9	11.5	8.4	7.3	7.8	8.8
Mastek	8	277	333	BUY	39.9	39.8	39.6	43.2	6.9	6.9	7.0	6.4	15.9	15.0	13.3	12.8
Tier-2 IT AVG									12.3	12.4	13.0	10.9	22.7	19.9	17.1	18.3
Tier-2 IT Median									12.5	11.4	12.7	11.3	20.0	19.5	18.6	19.3

Source: HSIE Research, #Dec YE,* FY20 Actual numbers



Financials

Consolidated Income Statement

YE March (Rs bn)	FY17	FY18	FY19	FY20	FY21E	FY22E
Net Revenues (USD mn)	6,975	7,838	8,632	9,936	9,919	10,741
Growth (%)	11.9	12.4	10.1	15.1	-0.2	8.3
Net Sales	467.23	505.69	604.27	706.78	724.08	794.85
Growth (%)	14.2	8.2	19.5	17.0	2.4	9.8
Cost of Revenue	308.90	332.37	392.67	452.95	473.47	509.97
SG&A Expenses	55.24	58.93	71.91	86.90	85.80	95.79
EBITDA	103.09	114.39	139.69	166.93	164.82	189.09
Depreciation	8.35	14.52	21.48	26.63	28.38	30.14
EBIT	94.74	99.87	118.21	140.30	136.44	158.95
EBIT (%)	20.3	19.7	19.6	19.9	18.8	20.0
EBIT Growth (%)	15.2	5.4	18.4	18.7	-2.8	16.5
Other Income net	10.24	11.78	9.78	6.84	5.60	12.14
Interest	0.89	0.69	1.74	5.05	3.30	3.30
PBT	104.09	110.96	126.25	142.09	138.74	167.79
Tax (incl deferred)	19.52	23.17	24.81	29.38	33.30	40.27
RPAT	84.57	87.79	101.22	112.39	105.12	127.20
APAT	81.54	87.80	101.23	110.62	105.12	127.20
APAT Growth (%)	10.9	7.7	15.3	9.3	-5.0	21.0
EPS	30.1	32.4	37.3	40.8	38.8	46.9
EPS Growth (%)	10.9	7.7	15.3	9.3	-5.0	21.0

Source: Company, HSIE Research

Consolidated Balance Sheet

YE March (Rs bn)	FY17	FY18	FY19	FY20	FY21E	FY22E
SOURCES OF FUNDS						
Share Capital – Equity	2.85	2.78	2.71	5.43	5.42	5.42
Reserves	326.64	361.08	410.95	507.24	584.70	679.36
Total Shareholders' Funds	329.49	363.86	413.66	512.67	590.12	684.78
Total Debt	4.38	3.80	37.01	46.93	46.93	46.93
Long Term Provisions & Others	9.22	11.92	18.30	49.07	49.07	49.07
TOTAL SOURCES OF FUNDS	344.82	379.58	470.00	610.21	687.66	782.32
APPLICATION OF FUNDS						
Net Block	87.31	119.54	138.27	213.36	204.00	186.96
CWIP	4.48	3.20	2.35	4.00	4.00	4.00
Goodwill	65.04	67.99	90.61	161.54	161.54	161.54
Investments	1.60	0.43	0.85	0.85	0.85	0.85
Other non-current assets	34.56	40.89	56.45	65.19	65.19	65.19
Total Non Current Assets	192.99	232.05	288.53	444.94	435.58	418.54
Debtors	83.01	96.39	117.06	141.31	144.77	158.92
Cash & Equivalents	101.90	66.35	100.92	119.57	143.87	242.50
Other Current Assets	79.72	85.44	79.24	123.24	123.26	123.35
Total Current Assets	264.63	248.18	297.22	384.12	411.91	524.77
Creditors	8.01	9.18	13.05	11.66	11.95	13.11
Other Current Liabilities & Provns	104.79	91.47	102.70	207.19	147.88	147.88
Total Current Liabilities	112.80	100.65	115.75	218.85	159.82	160.99
Net Current Assets	151.83	147.53	181.47	165.27	252.08	363.78
TOTAL APPLICATION OF FUNDS	344.82	379.58	470.00	610.21	687.66	782.32



Consolidated Cash Flow

YE March (Rs bn)	FY17	FY18	FY19	FY20	FY21E	FY22E
Reported PBT	104.09	110.96	126.25	142.09	138.74	167.79
Non-operating & EO items	-7.08	-5.11	-7.61	-1.74	-4.26	-9.23
Interest expenses	0.19	0.22	1.24	2.51	3.30	3.30
Depreciation	8.28	13.83	20.73	34.20	28.38	30.14
Working Capital Change	3.21	-12.34	-24.66	-15.60	-3.20	-13.07
Tax paid	-20.07	-23.56	-26.21	-25.58	-33.30	-40.27
OPERATING CASH FLOW (a)	88.62	84.00	89.74	135.88	129.67	138.67
Capex	-44.08	-54.51	-62.93	-79.57	-78.33	-13.11
Free cash flow (FCF)	44.54	29.49	26.81	56.31	51.34	125.56
Investments	-0.14	1.17	-0.42	-	-	-
INVESTING CASH FLOW (b)	-37.14	-48.23	-55.74	-77.83	-74.07	-3.88
Debt Issuance	-3.95	-1.48	36.14	-2.46	-	-
Interest expenses	-0.19	-0.14	-0.71	-1.36	-3.30	-3.30
FCFE	40.40	27.87	62.24	52.49	48.04	122.26
Share capital Issuance	0.03	-	-	-	-0.01	-
Dividend/Buyback	-40.69	-55.31	-53.21	-16.25	-27.66	-32.54
FINANCING CASH FLOW (c)	-44.80	-56.93	-17.78	-20.07	-30.97	-35.84
NET CASH FLOW (a+b+c)	6.68	-21.16	16.22	37.98	24.62	98.94
Closing Cash & Equivalents	101.90	66.35	100.92	119.57	143.87	242.50


Source: Company, HSIE Research

Key Ratios

	FY17	FY18	FY19	FY20	FY21E	FY22E
PROFITABILITY (%)						_
EBIT Margin	20.3	19.7	19.6	19.9	18.8	20.0
APAT Margin	17.5	17.4	16.8	15.7	14.5	16.0
RoE	26.9	25.3	26.0	23.8	19.0	19.9
RoIC or Core RoCE	34.9	28.4	27.8	25.9	20.0	22.3
RoCE	25.6	24.4	24.2	21.2	16.6	17.6
EFFICIENCY						
Tax Rate (%)	18.8	20.9	19.7	20.7	24.0	24.0
Total Asset Turnover (x)	1.0	1.1	1.0	0.9	0.9	0.8
Debtors (days)	65	70	71	73	73	73
Other current assets (days)	62	62	48	64	62	57
Payables (days)	6	7	8	6	6	6
Other current liab & provn (days)	82	66	62	107	75	68
Cash Conversion Cycle (days)	41	60	49	24	55	56
Net Debt/EBITDA (x)	-0.9	-0.5	-0.5	-0.4	-0.6	-1.0
Net Debt/Equity (x)	-0.3	-0.2	-0.2	-0.1	-0.2	-0.3
Interest Coverage (x)	106	145	68	28	41	48
PER SHARE DATA						
EPS (Rs/sh)	30.1	32.4	37.3	40.8	38.8	46.9
CEPS (Rs/sh)	34.3	37.7	45.2	51.3	49.2	58.0
DPS (Rs/sh)	24.0	12.0	10.0	14.0	17.0	20.0
BV (Rs/sh)	122.1	134.1	152.9	189.6	218.1	253.0
VALUATION						
P/E	17.0	15.8	13.7	12.5	13.2	10.9
P/BV	4.2	3.8	3.3	2.7	2.3	2.0
EV/EBITDA	12.5	11.6	9.5	7.9	7.8	6.3
OCF/EV (%)	6.9	6.3	6.8	10.3	10.0	11.6
FCF/EV (%)	3.5	2.2	2.0	4.3	7.6	12.6
FCFE/mkt cap (%)	3.1	2.1	4.7	4.0	7.4	12.4
Dividend Yield (%)	4.7	2.3	2.0	2.7	3.3	3.9



RECOMMENDATION HISTORY



Date	CMP	Reco	Target
10-May-19	566	BUY	625
5-Jul-19	508	BUY	653
8-Aug-19	512	BUY	625
27-Aug-19	547	BUY	625
22-Sep-19	525	BUY	625
4-Oct-19	539	BUY	638
24-Oct-19	548	BUY	625
7-Jan-20	582	BUY	640
18-Jan-20	599	BUY	665
2-Mar-20	534	ADD	675
18-Mar-20	451	BUY	560
6-Apr-20	406	BUY	525
8-May-20	511	BUY	565

From 2nd March 2020, we have moved to new rating system

Rating Criteria

BUY: >+15% return potential
ADD: +5% to +15% return potential
REDUCE: -10% to +5% return potential
SELL: >10% Downside return potential



Disclosure:

We, Apurva Prasad, MBA, Amit Chandra, MBA & Vinesh Vala, MBA, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. **does not have** any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate **does not have** any material conflict of interest.

Any holding in stock -No

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066 Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

HDFC securities

Institutional Equities

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Board: +91-22-6171-7330 www.hdfcsec.com